Hanmi Fine Chemical Launches ‘high-tech CDMO’ Business – QNT Press Release


CDMO business initiated such as mRNA vaccine raw materials peptides

10 billion KRW invested in Hanmi Fine Chemical facility expansion

SEOUL, South Korea, May 22, 2022 /PRNewswire/ — Hanmi Fine Chemical (hereinafter Hanmi FC) a subsidiary of Hanmi Pharmaceutical Group specializing in APIs(Active Pharmaceutical Ingredient) development and manufacturing, is now accelerating a new business, expanding its specialties from ongoing APIs to ‘high-tech CDMO ‘ services.

Due to the COVID-19 pandemic, there has been an increase in the global demand for high-level, synthetic bio-pharmaceutical raw materials, such as those used in mRNA vaccines, including lipid nanoparticles (LNP), nucleotides, capping materials, polyethylene glycol (PEG) derivatives, and peptides. As such, on May 23, 2022Hanmi FC (CEO Chang Young-kil) announced that it will launch its areas of business to include CDMO projects in relevant fields.

Full story available on Benzinga.com



Source link

Recommended For You

About the Author: News Center